MENU
Aim higher

LeukeMab

Design of an anti-CD160 mAb targeting CLL, HCL and immune cells for leukemia immunotherapy

The goal of the project is to develop a new monoclonal antibody (mAb) to treat B-Cell Chronic Lymphocytic Leukemia (CLL). The project partners will develop, produce, and validate a therapeutic mAb to simultaneously kill leukemia tumour cells and activate the antitumor immune response. This would be a major improvement in terms of efficacy and toxicity compared to current treatments. At the end of the project, the product will be ready to start regulatory and clinical development.
Acronym: 
LeukeMab
Project ID: 
10 865
Ranking: 
74
Cut-off: 
6
Start date: 
01-03-2017
Project Duration: 
24months
Project costs: 
989 223.00€
Technological Area: 
Cytology, Cancerology, Oncology
Market Area: 
Drug delivery and other equipment (including kidney dialysis machines)